FDA news

Brexafemme approved for recurrent yeast infection

Brexafemme Approved For Recurrent Yeast Infections

The Food and Drug Administration (FDA) has approved Brexafemme for a second indication for reduction in incidence of recurrent vulvovaginal candidiasis, Scynexis announced Thursday “Brexafemme was already the…

FDA announces Project Orbis

The U.S. Food and Drug Administration (FDA) has announced Project Orbis, a new initiative from the FDA Oncology Center of Excellence (OCE), which will provide “a framework for…

Reader Survey

Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.